447 related articles for article (PubMed ID: 3076125)
21. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
22. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
23. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
Nagata Y; Hidaka Y; Ishida F; Kamei T
Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097
[TBL] [Abstract][Full Text] [Related]
24. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
Gerson RJ; MacDonald JS; Alberts AW; Chen J; Yudkovitz JB; Greenspan MD; Rubin LF; Bokelman DL
Exp Eye Res; 1990 Jan; 50(1):65-78. PubMed ID: 2307197
[TBL] [Abstract][Full Text] [Related]
25. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Sirtori CR
Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Cheng H; Sutton SC; Pipkin JD; Zentner GM; Rogers JD; Schwartz JI; Mitchel YB; Grasing K; Schwartz MS; Amin RD
Pharm Res; 1993 Nov; 10(11):1683-7. PubMed ID: 8290485
[TBL] [Abstract][Full Text] [Related]
27. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Garnett WR
Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
[TBL] [Abstract][Full Text] [Related]
28. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
29. Long-term clinical tolerance of lovastatin and simvastatin.
Bilheimer DW
Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
[TBL] [Abstract][Full Text] [Related]
30. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
[TBL] [Abstract][Full Text] [Related]
31. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
Hoeg JM; Brewer HB
JAMA; 1987 Dec; 258(24):3532-6. PubMed ID: 3316727
[TBL] [Abstract][Full Text] [Related]
32. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
[TBL] [Abstract][Full Text] [Related]
33. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Desager JP; Horsmans Y
Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors.
Sirtori CR
Pharmacol Res; 1990; 22(5):555-63. PubMed ID: 2126139
[TBL] [Abstract][Full Text] [Related]
36. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Krasovec M; Elsner P; Burg G
Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
[TBL] [Abstract][Full Text] [Related]
37. [Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits].
Oogushi K
Fukuoka Igaku Zasshi; 1991 Feb; 82(2):36-47. PubMed ID: 2022360
[TBL] [Abstract][Full Text] [Related]
38. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.
Duane WC; Hunninghake DB; Freeman ML; Pooler PA; Schlasner LA; Gebhard RL
Hepatology; 1988; 8(5):1147-50. PubMed ID: 3047037
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics and practical applications of simvastatin.
Mauro VF
Clin Pharmacokinet; 1993 Mar; 24(3):195-202. PubMed ID: 8343198
[TBL] [Abstract][Full Text] [Related]
40. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
